Varegacestat
As of the edition of 20 October 2026, Varegacestat is a small molecule: in active development; acts on PSEN1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 7, 1 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PSEN1 | Presenilin-1 | P49768 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 1 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2013 to now |
| Immunome | Lead sponsor of trials | 2021 to now |